This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of medications called JAK inhibitors, using an acronym that assumes the ...

Tailored use of ruxolitinib, an inhibitor of the JAK/STAT signalling pathway, allows experimentally controlled induction of innate immunity and in turn viral clearance or persistence. Clearly, during ...

Our work aims to explore the involvement of Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signalling pathway in proinflammatory T cells differentiation and disease ...

Baricitinib is an oral JAK 1/2 inhibitor that interrupts the signaling pathway of interferon-gamma by blocking these enzymes. This helps reduce inflammation and suppress the overactive immune ...

AbbVie's next-generation immunology drugs targeting the IL23 and JAK pathways should help mitigate the competitive threats facing Humira over the next five years. AbbVie has had to depend on ...